Arbor Biotech to Present Latest Data on HPV mRNA Cancer Vaccine ABO2101 and CD19/CD3 T-Cell Engager mRNA Therapeutic at AACR 2024

Mar 21, 2024 08:28 CST Updated 08:28

Abogen

Nucleic Acid Drug Developer

March 20, 2024, Abogen Biosciences Co., Ltd.(hereinafter referred to as "Abogen")Announced that it will be at the 2024 American Association for Cancer Research（AACR）Announced at the annual meeting in the form of a poster, independently developed byBased on the Novel mRNA Tumor Immunological FrameworkHPVCancer VaccineResearch andmRNA Drug Encoding CD19/CD3 T Cell Engager for the Treatment of B-Cell Hematologic MalignanciesThe latest data from the study.

As one of the most authoritative academic conferences globally, the 2024 AACR Annual Meeting will be held in San Diego, USA, from April 5 to 10, 2024.

ABO2101 is a product based onAbogenThe latest generation of innovative tumor vaccine platform-based mRNA therapeutic cancer vaccines.This tumor vaccine backbone contains elements such as an antigen processing-enhancing domain, a lysosomal transport domain, and an antigen-presenting cell (APC) activation stimulant, which can enhance class I and class II antigen presentation and APC maturation, thereby strengtheningTumor SpecificityT Cell ResponseIn various preclinical early and late-stage tumor animal experimental models, ABO2101 demonstrated stronger specific T-cell responses and better tumor suppression effects compared to other similar vaccine products, while showing good safety. In addition, in tumor prevention and adjuvant treatment models, ABO2101 was able to prevent tumor formation at extremely low doses, indicating the product's significant potential for cancer prevention and treatment in clinical applications.

In this study, the research and development team utilized Abogen's proprietary mRNA technology and lipid nanoparticles.（LNP）Delivery system, developed a series of encoded CD19/CD3 T cell engagers（TCE）The mRNA drug significantly improved the pharmacokinetic (PK) properties of the active protein in vivo, increased drug exposure, and reduced toxicity.

In PK studies conducted in mice and non-human primates, mRNA-encoded drugs exhibited more favorable pharmacokinetic properties, significantly increasing drug exposure and half-life compared to protein-based drugs. This resulted in better anti-tumor activity at lower doses and less frequent dosing. In terms of toxicity, mRNA-encoded drugs inducedIL-6Cytokines were significantly reduced, indicating a significant decrease in clinical settings.CRSRisk.

Currently, an mRNA-encoded CD19/CD3 TCE has been developed for investigator-initiated clinical research targeting relapsed and/or refractory acute lymphoblastic leukemia. Preliminary clinical data shows thatProduct PKValidated in clinical settings,It has demonstrated good safety and biomarker activity validation in multiple patients.

About AACR

American Association for Cancer Research（American Association for Cancer Research，AACR）Founded in 1907, it is the world's oldest and largest scientific organization dedicated to accelerating the conquest of cancer, aiming to promote research and development in the field of cancer and related biomedical sciences. It currently has over 58,000 members in 141 countries and regions.

American Association for Cancer Research（AACR）The annual meeting is one of the oldest and largest academic conferences on cancer research globally. The conference focuses on all aspects of high-quality cancer research and innovation, serving as the focal point of global cancer research and bringing together the most cutting-edge research achievements in the field.

About Abogen

Abogen is a company focused on messenger ribonucleic acid (mRNA).（mRNA）An innovative biopharmaceutical company in drug research and development. It possesses industry-leading, proprietary intellectual property.mRNAAnd the nanotechnology delivery platform, is one of the few in China with complete value chain capabilities.mRNAPharmaceutical R&D enterprises, covering frommRNADesign, formulation development, and large-scale production. The company has established a rich product pipeline, covering includingmRNAIncluding the prevention and treatment of infectious diseases such as COVID-19 vaccines, tumor immunology, protein replacement therapy, and other fields.2022Year9Month, Abogen's novel coronavirusmRNAVaccineARCoVGranted Emergency Use Authorization in Indonesia, becoming the first self-developed Chinese product to receive overseas marketing approval.mRNAVaccine.

Source: Abogen

E.N.D